/ Unlabelled / International Textbook of Diabetes Mellitus, 4th Ed., Excerpt #11: Epidemiology and Risk Factors for Type 1 Diabetes … – Diabetes In Control

Monday, February 15, 2016

International Textbook of Diabetes Mellitus, 4th Ed., Excerpt #11: Epidemiology and Risk Factors for Type 1 Diabetes … – Diabetes In Control

Date - 

DeFronzoCoverEstablished type 1 diabetes

Clinical onset

In industrialized countries, 20–40% of T1DM patients younger compared to twenty years present along with diabetic ketoacidosis [118]. After adjusting for age, gender, ethnicity, diabetes type, and family history of diabetes, diabetic ketoacidosis at diagnosis was associated along with reduced family income, much less desirable good health insurance coverage, and reduced parental education [3]. Younger youngsters present along with much more significant symptoms at diagnosis, due to the fact that youngsters younger compared to 7 years old have actually lost on standard 80% of the islets, compared to 60% in those 7–14 years old and 40% in those older compared to 14 years [119]. Case fatality in industrialized countries ranges between 0.4–0.9% [120]. The 2 diabetic ketoacidosis and onset death are largely preventable, due to the fact that most of the patients have actually typical symptoms of polyuria, polydipsia, and fat loss 2–4 weeks prior to diagnosis. The diagnosis is straightforward in almost all of cases, based on the symptoms, random blood glucose over 200mg dL−1 and/or HbA1c >7%.

Traditionally, nearly all of youngsters along with newly diagnosed T1DM were hospitalized. much more recently, an increasing proportion of new-onset youngsters have actually been managed on an outpatient basis, especially in urban centers along with specialized diabetes education and treatment facilities. Hospitalization at onset does not enhance short-term outcomes such as re-admission for diabetic ketoacidosis or significant hypoglycemia [118], if adequate family education and follow-up is available on outpatient basis.

Remission (honeymoon period)

Shortly after clinical onset, most T1DM patients experience a transient fall in insulin need as a result of improved β-cell function. Total and partial remissions have actually been reported in, respectively, 2–12% and 18–62% of young T1DM patients [118]. Older age and much less significant first presentation of T1DM and reduced or absent ICA or IA-2 [121] have actually been consistently associated along with deeper and longer remission. Evidence relating GAD autoantibodies [121,122], non-Caucasian origin, HLA-DR3 allele, female gender, and family history of T1DM to a much less significant presentation, higher frequency of remission, and slower deterioration of insulin secretion is inconclusive. Most studies agree that preserved beta-cell function is associated along with much better glycemic regulate (reduced HbA1c) and preserved α-cell glucagon response to hypoglycemia.

The natural remission is constantly temporary, ending along with a gradual or abrupt boost in exogenous insulin requirements. Destruction of beta cells is finish within 3 years of diagnosis in most young children, especially those along with the HLA-DR3/4 genotype. It is considerably slower and frequently only partial in older patients [123], 15% of whom have actually still some beta-cell function preserved 10 years after diagnosis.

Acute complications

Acute problems of T1DM (diabetic ketoacidosis, hypoglycemia, and infections) are described in detail in others chapters.The risk of hospital admission for acute complication is 30/100 patient-years in the very first year of the illness and 20/100 patient-years in the subsequent 3 years [118]. An estimated 26% of the patients have actually at least one episode of significant hypoglycemia within the first 4 years of diagnosis. The incidence of significant hypoglycemic episodes varies between 6 and twenty per 100 person-years, and enhances along with younger age, longer duration of diabetes, intensity of insulin treatment, reduced levels of HbA1c, and in older youngsters along with presence of underinsurance and psychiatric disorders [118,124]. The incidence of ketoacidosis is regarding 8 per 100 person-years and enhances along with age in girls; the risk of ketoacidosis additionally enhances along with greater HbA1c, greater reported insulin dose, and in older youngsters along with limited access to care as a result of underinsurance and presence of psychiatric disorders [124]. Interestingly, most of ketoacidosis and/or hypoglycemic episodes occur among 20% of youngsters that have actually recurrent events.

Morbidity and mortality

Insulin treatment dramatically prolongs survival yet it does not cure diabetes. Excess mortality appears to be lowest in Scandinavia, intermediate in the US, and highest in countries where T1DM is rare, for example, Japan, probably as a result of a combination of the quality of care and access. On the others hand, 40% of the patients survive over 40 years and a half of these have actually no serious complications. Several studies have actually shown that survival in T1DM has actually improved over time [125]. The Pittsburgh Epidemiology of Diabetes problems (EDC) study cohort has actually recently shown that the life expectancy for those diagnosed 1965–1980 was 15 years higher compared to participants diagnosed 1950–1964, a difference that persisted regardless of sex or pubertal status at diagnosis [126]. The 2 the Finnish Diabetic Nephropathy (FinnDiane) study and the Pittsburgh EDC study report that in the absence of renal illness and microalbuminuria, the long term mortality risk in T1DM is not increased compared along with the general population [127].

References:

  1. Mayer-Davis E: boost in prevalence of type 1 diabetes from the SEARCH for Diabetes in Youth Study: 2001 to 2009, 2012. [Abstract]
  2. Lawrence JM: Trends in incidence of type 1 diabetes among non-Hispanic white youth in the US, 2002–2009, 2012. [Abstract]
  3. Rewers A, Klingensmith G, Davis C, et al.: Presence of diabetic ketoacidosis at diagnosis of diabetes mellitus in youth: the Search for Diabetes in Youth Study. Diary of Pediatrics 2008;121(5):e1258–e1266.
  4. Patterson CC, Gyurus E, Rosenbauer J, et al.: Trends in childhood type 1 diabetes incidence in Europe throughout 1989–2008: evidence of non-uniformity over time in rates of increase. Diabetologia 2012;55(8):2142–2147.
  5. Fourlanos S, Varney MD, Tait BD, et al.: The rising incidence of type 1 diabetes is accounted for by cases along with lower-risk human leukocyte antigen genotypes. Diabetes Care 2008;31(8):1546–1549.
  6. Liese AD, D’Agostino RB, Jr., Hamman RF, et al.: The burden of diabetes mellitus among US youth: prevalence estimates from the SEARCH for Diabetes in Youth Study. Pediatrics 2006; 118(4):1510–1518.
  7. The Environmental Determinants of Diabetes in the Young (TEDDY) Study: Annals of the N Y Academy of Sciences 2008; 1150:1–13.
  8. Harjutsalo V, Sjoberg L, Tuomilehto J: Time trends in the incidence of type 1 diabetes in Finnish children: a cohort study. Lancet 2008;371(9626):1777–1782.
  9. Haynes A, Bulsara MK, Bower C, et al.: Cyclical variation in the incidence of childhood type 1 diabetes in Western Australia (1985–2010). Diabetes Care 2012; 35(11):2300–2302.
  10. Borchers AT, Uibo R, Gershwin ME:The geoepidemiology of type 1 diabetes. Autoimmunity Reviews 2010;9(5):A355–A365.
  11. The DiaMond Project Group: Incidence and trends of childhood type 1 diabetes international 1990–1999. Diabetic Medicine 2006;23(8):857–866.
  12. GreenA, Patterson CC: Trends in the incidence of childhood-onset diabetes in Europe 1989–1998. Diabetologia 2001;44(Suppl 3): B3–B8.
  13. Karvonen M, Viik-Kajander M, Moltchanova E, et al.: Incidence of childhood type 1 diabetes worldwide. Diabetes Mondiale (Dia-Mond) Project Group. Diabetes Care 2000;23(10):1516–1526.
  14. Zhang H, Xia W, Yu Q, et al. Increasing incidence of type 1 diabetes in youngsters aged 0–14 years in Harbin, China (1990–2000). Primary Care Diabetes 2008;2(3):121–126.
  15. Dabelea D, Bell RA, D’Agostino RB, Jr,., et al.: Incidence of diabetes in youth in the United States. JAMA 2007;297(24):2716–2724.
  16. Kostraba JN, Gay EC, Cai Y, et al.: Incidence of insulin-dependent diabetes mellitus in Colorado. Epidemiology 1992;3:232–238.
  17. Gujral JS, McNally PG, Botha JL, Burden AC: Childhood-onset diabetes in the white and South Asian population in Leicestershire, UK. Diabetic Medicine 1994;11(6):570–572.
  18. Dahlquist GG, Nystrom L, Patterson CC: Incidence of type 1 diabetes in Sweden among people aged 0–34 years, 1983–2007: an analysis of time trends. Diabetes Care 2011;34(8):1754–1759.
  19. Bruno G,Merletti F, Biggeri A, et al.: Increasing trend of type I diabetes in youngsters and young adults in the province of Turin (Italy). Analysis of age, period and birth cohort effects from 1984 to 1996. Diabetologia 2001;44(1):22–25.
  20. Gale EA, Gillespie KM: Diabetes and gender. Diabetologia 2001; 44(1):3–15.
  21. Serban V, Timar R, Dabelea D, et al.: The epidemiology of childhood-onset type 1 diabetes mellitus in Romania. ONROCAD Study Group. National Romanian Organisation for the Care of Diabetic youngsters and Adolescents. Diary of Pediatric Endocrinology and Metabolism 2001;14(5):535–541.
  22. Diabetes Epidemiology Research Global Group: Secular trends in incidence of childhood IDDM in 10 countries. Diabetes 1990;39:858–864.
  23. EURODIAB ACE Study Group: Variation and trends in incidence of childhood diabetes in Europe. Lancet 2000;355(9207):873–876.
  24. Rosenbauer J, Herzig P, von Kries R, et al.: Temporal, seasonal, and geographical incidence patterns of type I diabetes mellitus in youngsters under 5 years of age in Germany. Diabetologia 1999; 42(9):1055–1059.
  25. Schoenle EJ, Lang-Muritano M, Gschwend S, et al.: Epidemiology of type I diabetes mellitus in Switzerland: steep rise in incidence in under 5 year old youngsters in the past decade. Diabetologia 2001;44(3):286–289.
  26. Verge CF, Gianani R, Kawasaki E, et al.: Prediction of type I diabetes in first-degree relatives using a combination of insulin, GAD, and ICA512bdc/IA-2 autoantibodies. Diabetes 1996;45(7):926–933.
  27. Williams AJ, Bingley PJ, Bonifacio E, et al.: A novel micro-assay for insulin autoantibodies. Diary of Autoimmunity 1997;10(5): 473–478.
  28. Robles DT, Eisenbarth GS,Wang T, et al.: Identification of youngsters along with early onset and higher incidence of anti-islet autoantibodies. Clinical Immunology 2002;102(3):217–224.
  29. Kupila A, Keskinen P, Simell T, et al. Genetic risk determines the emergence of diabetes-associated autoantibodies in young children. Diabetes 2002;51(3):646–651.
  30. Orban T, Sosenko JM,Cuthbertson D, et al. Pancreatic islet autoantibodies as predictors of type 1 diabetes in the Diabetes Prevention Trial-Type 1. Diabetes Care 2009;32(12):2269–2274.
  31. Siljander HT, Simell S, Hekkala A, et al.: Predictive characteristics of diabetes-associated autoantibodies among youngsters along with HLA-conferred illness susceptibility in the general population. Diabetes 2009;58(12):2835–2842.
  32. Redondo MJ, Jeffrey J, Fain PR, et al.: Concordance for islet autoimmunity among monozygotic twins. brand-new England Diary of Medicine 2008;359(26):2849–2850.
  33. Harjutsalo V, Reunanen A, Tuomilehto J: Differential transmission of type 1 diabetes from diabetic fathers and mothers to their offspring. Diabetes 2006; 55(5):1517–1524.
  34. Koczwara K, Bonifacio E, Ziegler AG: Transmission of maternal islet antibodies and risk of autoimmune diabetes in offspring of mothers along with type 1 diabetes. Diabetes 2004;53(1):1–4.
  35. Rewers M, Bugawan TL, Norris JM, et al.: Newborn screening for HLA markers associated along with IDDM: Diabetes Autoimmunity Study in the Young (DAISY). Diabetologia 1996;39:807–812.
  36. Deschamps I, Khalil I. The role of DQ alpha-beta heterodimers in genetic susceptibilty to insulin-dependent diabetes. Diabetes/Metabolism Reviews 1993;9:71–92.
  37. Valdes AM, Erlich HA, Noble JA: Human leukocyte antigen class I B and C loci contribute to Type 1 Diabetes (T1D) susceptibility and age at T1D onset. Human Immunology 2005;66(3): 301–313.
  38. Nejentsev S, Howson JM, Walker NM, et al.: Localization of type 1 diabetes susceptibility to the MHC class I genes HLA-B and HLA-A. Nature 2007;450(7171):887–892.
  39. Aly TA, Ide A, Jahromi MM, et al.: Extreme genetic risk for type 1A diabetes. PNAS 2006;103(38):14074–14079.
  40. Baschal EE, Aly TA, Babu SR, et al.: HLA-DPB1*0402 protects versus type 1A diabetes autoimmunity in the highest risk DR3-DQB1*0201/DR4-DQB1*0302 DAISY population. Diabetes 2007;56(9):2405–2409.
  41. Steck AK, Armstrong TK, Babu SR, Eisenbarth GS: Stepwise or linear decrease in penetrance of type 1 diabetes along with lower-risk HLA genotypes over the past 40 years. Diabetes 2011;60(3):1045–1049.
  42. Erlich H, Valdes AM, Noble J, et al.: HLA DR-DQ haplotypes and genotypes and type 1 diabetes risk: analysis of the type 1 diabetes genetics consortium families. Diabetes 2008;57(4):1084–1092.
  43. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 2007;447(7145): 661–678.
  44. Steck AK,Wong R,Wagner B, et al.: Effects of non-HLA gene polymorphisms on development of islet autoimmunity and type 1 diabetes in a population along with high-risk HLA-DR,DQ genotypes. Diabetes 2012;61(3):753–758.
  45. Vang T, Congia M, Macis MD, et al.: Autoimmune-associated lymphoid tyrosine phosphatase is a gain-of-function variant. Nature Genetics 2005;37(12):1317–1319.
  46. Rieck M, Arechiga A, Onengut-Gumuscu S, et al.: Genetic variation in PTPN22 corresponds to altered function of T and B lymphocytes. Diary of Immunology 2007;179(7):4704–4710.
  47. Yu L, Cuthbertson DD, Maclaren N, et al.: Expression of GAD65 and islet cell antibody (ICA512) autoantibodies among cytoplasmic ICA+ relatives is associated along with eligibility for the Diabetes Prevention Trial-Type 1. Diabetes 2001;50(8):1735–1740.
  48. Wenzlau JM, Moua O, Sarkar SA, et al.: SlC30A8 is a serious target of humoral autoimmunity in type 1 diabetes and a predictive marker in prediabetes. Annals of the N Y Academy of Sciences 2008; 1150:256–259.
  49. Achenbach P, Schlosser M, Williams AJ, et al.: Combined testing of antibody titer and affinity enhances insulin autoantibody measurement: Diabetes Antibody Standardization Program. Clinical Immunology 2007;122(1):85–90.
  50. Torn C, Mueller PW, Schlosser M, et al.: Diabetes Antibody Standardization Program: evaluation of assays for autoantibodies to glutamic acid decarboxylase and islet antigen-2. Diabetologia 2008;51(5):846–852.
  51. Achenbach P, Bonifacio E,Williams AJ, et al.: Autoantibodies to IA-2beta enhance diabetes risk assessment in high-risk relatives. Diabetologia 2008;51(3):488–492.
  52. Steck AK, Johnson K, Barriga KJ, et al.: Age of islet autoantibody appearance and mean levels of insulin, yet not GAD or IA-2 autoantibodies, predict age of diagnosis of type 1 diabetes: Diabetes Autoimmunity Study in the Young. Diabetes Care 2011; 34(6):1397–1399.
  53. Bingley PJ, Gale EA: Progression to type 1 diabetes in islet cell antibody-positive relatives in the European Nicotinamide Diabetes Intervention Trial: the role of additional immune, genetic and metabolic markers of risk. Diabetologia 2006;49(5):881–890.
  54. Ekoé J-M, Rewers M,Williams R, Zimmet P (eds.): The Epidemiology of Diabetes Mellitus Textbook. JohnWiley & Sons, Ltd., 2008.
  55. Ziegler A-G, Hillebrand B, Rabl W, et al.: On the appearance of islet associated autoimmunity in offspring of diabetic mothers: a prospective study from birth. Diabetologia 1993;36:402–408.
  56. Barker JM, Barriga KJ, Yu L, et al.: Prediction of autoantibody positivity and progression to type 1 diabetes: Diabetes Autoimmunity Study in the Young (DAISY). Diary of Clinical Endocrinology & Metabolism 2004;89(8):3896–3902.
  57. Kimpimaki T, Knip M: Disease-associated autoantibodies as predictive markers of type 1 diabetes mellitus in siblings of affected children. Diary of Pediatric Endocrinology and Metabolism 2001;14(Suppl 1):575–587.
  58. The Environmental Determinants of Diabetes in the Young (TEDDY) study: study design. Pediatric Diabetes 2007;8(5): 286–298.
  59. Siljander HT, Veijola R, Reunanen A, et al.: Prediction of type 1 diabetes among siblings of affected youngsters and in the general population. Diabetologia 2007;50(11):2272–2275.
  60. Achenbach P, Koczwara K, Knopff A, et al.: Mature high-affinity immune responses to (pro) insulin anticipate the autoimmune cascade that leads to type 1 diabetes. Diary of Clinical Investigation 2004;114(4):589–97.
  61. Laakso M, Pyorala K: Age at onset and kind of diabetes. Diabetes Care 1985;8:114–117.
  62. Fuchtenbusch M, Ferber K, Standl E, Ziegler AG: Prediction of type 1 diabetes postpartumin patients along with gestational diabetes mellitus by combined islet cell autoantibody screening: a prospective multicenter study. Diabetes 1997;46(9):1459–1467.
  63. Turner R, Stratton I,Horton V, et al.: UKPDS 25: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin need in type 2 diabetes. UK Prospective Diabetes Study Group. Lancet 1997;350(9087):1288–1293.
  64. Chase HP, Dolan LM, Krischer JP, et al.: very first phase insulin release (FPIR) throughout the intravenous glucose tolerance test (IV-GTT) as a risk factor for type 1 diabetes. Diary of Pediatrics 2001; 138(2):244–249.
  65. Keskinen P, Korhonen S, Kupila A, et al.: First-phase insulin response in young healthy and balanced youngsters at genetic and immunological risk for Type I diabetes. Diabetologia 2002;45(12):1639–1648.
  66. Eisenbarth GS, Verge CF, Allen H, Rewers MJ: The design of trials for prevention of IDDM. Diabetes 1993;42(7):941–947.
  67. Keymeulen B, Walter M, Mathieu C, et al.: Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass. Diabetologia 2010;53(4):614–623.
  68. Sosenko JM, Palmer JP, Greenbaum CJ, et al.: Increasing the accuracy of oral glucose tolerance testing and extending its application to people along with normal glucose tolerance for the prediction of type 1 diabetes: the Diabetes PreventionTrial -Type 1. Diabetes Care 2007;30(1):38–42.
  69. Sosenko JM, Krischer JP, Palmer JP, et al.: A risk score for type 1 diabetes derived from autoantibody-positive participants in the Diabetes Prevention Trial-Type 1. Diabetes Care 2008;31(3): 528–533.
  70. Leech NJ, Rowe RE, Bucksa J, McCulloch DK: HbA1c could be an early indicator of islet cell dysfunction. Autoimmunity 1993;15(Suppl):75. [Abstract]
  71. Stene LC, Barriga K, Hoffman M, et al.: Normal yet increasing hemoglobin A1c levels predict progression from islet autoimmunity to overt type 1 diabetes: Diabetes Autoimmunity Study in the Young (DAISY). Pediatric Diabetes 2006;7(5):247–253.
  72. International Expert Committee report on the role of the A1c assay in the diagnosis of diabetes. Diabetes Care 2009;32(7):1327–1334.
  73. Vehik K,Cuthbertson D, Boulware D, et al.: Performance of HbA1c as an early diagnostic indicator of type 1 diabetes in youngsters and youth. Diabetes Care 2012; 35(9):1821–1825.
  74. The Diabetes regulate and problems Trial Research Group: Effects of age, duration and treatment of insulin-dependent diabetes mellitus on residual B-cell function: observations throughout eligibility testing for the diabetes regulate and problems trial. Diary of Clinical Endocrinology & Metabolism 1987;65:30–36.
  75. The Diabetes regulate and problems Trial Research Group: Effect of intensive therapy on residual beta-cell function in patients along with type 1 diabetes in the diabetes regulate and problems trial. A randomized, controlled trial. Annals of Internal Medicine 1998;128(7):517–523.
  76. Sosenko JM, Palmer JP, Rafkin-Mervis L, et al.: Glucose and C-peptide adjustments in the perionset period of type 1 diabetes in the Diabetes Prevention Trial-Type 1. Diabetes Care 2008; 31(11):2188–2192.
  77. Greenbaum CJ, Beam CA, Boulware D, et al.: Fall in C-peptide throughout very first 2 years from diagnosis: evidence of at least two distinct phases from Composite Type 1 Diabetes TrialNet Data. Diabetes 2012;61(8):2066–2073.
  78. Kaprio J, Tuomilehto J, Koskenvuo M, et al.: Concordance for type 1 (insulin-dependent) and type 2 (non-insulin-dependent) diabetes mellitus in a population-based cohort of twins in Finland. Diabetologia 1992;35(11):1060–1067.
  79. Conrad B, Weidmann E, Trucco G, et al.: Evidence for superantigen involvement in insulin-dependent diabetes mellitus aetiology. Nature 1994;371(6495):351–355.
  80. Honeyman MC, Coulson BS, Stone NL, et al.: Association between rotavirus infection and pancreatic islet autoimmunity in youngsters at risk of creating type 1 diabetes. Diabetes 2000;49(8):1319–1324.
  81. Coppieters KT, Boettler T, von Herrat M: Virus infections in type 1 diabetes. Cold Spring Harbor Perspectives in Medicine 2012; 2(1):a007682.
  82. Stene LC, Oikarinen S, Hyoty H, et al.: Enterovirus infection and progression from islet autoimmunity to type 1 diabetes: the Diabetes and Autoimmunity Study in the Young (DAISY). Diabetes 2010;59(12):3174–3180.
  83. Oikarinen S, Martiskainen M, Tauriainen S, et al.: Enterovirus RNA in blood is linked to the development of type 1 diabetes. Diabetes 2011;60(1):276–279.
  84. Stene LC, Rewers M: Immunology in the clinic review series; concentrate on type 1 diabetes and viruses: the enterovirus link to type 1 diabetes: important review of human studies. Clinical & Experimental Immunology 2012;168(1):12–23.
  85. McKinney PA, Okasha M, Parslow RC, et al.: Early social mixing and childhood Type 1 diabetes mellitus: a case-regulate study in Yorkshire, UK. Diabetic Medicine 2000;17(3):236–242.
  86. Infections and vaccinations as risk factors for childhood type I (insulin-dependent) diabetes mellitus: a multicentre case-regulate investigation. EURODIAB Substudy 2 Study Group. Diabetologia 2000;43(1):47–53.
  87. Kaila B, Taback SP: The effect of day care exposure on the risk of creating type 1 diabetes: ameta-analysis of case-regulate studies. Diabetes Care 2001;24(8):1353–1358.
  88. Zinkernagel RM: Maternal antibodies, childhood infections, and autoimmune diseases. brand-new England Diary of Medicine 2001; 345(18):1331–1335.
  89. Graves PM, Barriga KJ, Norris JM, et al.: Lack of association between early childhood immunizations and beta-cell autoimmunity. Diabetes Care 1999;22(10):1694–1697.
  90. Hummel M, Fuchtenbusch M, Schenker M, Ziegler AG: No serious association of breast-feeding, vaccinations, and childhood viral diseases along with early islet autoimmunity in the German BABYDIAB Study. Diabetes Care 2000;23(7):969–974.
  91. Hyoty H, Hiltunen M, Reunanen A, et al.: Decline of mumps antibodies in type 1 (insulin-dependent) diabetic youngsters and a plateau in the rising incidence of type 1 diabetes after introduction of the mumps-measles-rubella vaccine in Finland. Childhood Diabetes in Finland Study Group. Diabetologia 1993;36(12):1303– 1308.
  92. Bingley PJ, Douek IF, Rogers CA, Gale EA: Influence of maternal age at delivery and birth order on risk of type 1 diabetes in childhood: prospective population based family study. Bart’s-Oxford Family Study Group. BMJ 2000;321(7258):420–424.
  93. Stene LC, Magnus P, Lie RT, et al.: Maternal and paternal age at delivery, birth order, and risk of childhood onset type 1 diabetes: population based cohort study. BMJ 2001;323(7309):369.
  94. Stene LC, Magnus P, Lie RT, et al.: Birth weight and childhood onset type 1 diabetes: population based cohort study. BMJ 2001;322(7291):889–892.
  95. Dahlquist GG, Patterson C, Soltesz G: Perinatal risk factors for childhood type 1 diabetes in Europe.The EURODIAB Substudy 2 Study Group. Diabetes Care 1999;22(10):1698–1702.
  96. Kyvik KO, Bache I, Green A, et al.: No association between birth weight and Type 1 diabetes mellitus: a twin-regulate study. Diabetic Medicine 2000;17(2):158–162.
  97. Lamb MM, Yin X, Zerbe GO, et al.: Height growth velocity, islet autoimmunity and type 1 diabetes development: the Diabetes Autoimmunity Study in the Young. Diabetologia 2009;52(10): 2064–2071.
  98. Martin JM, Trink B, Daneman D, et al.: Milk proteins in the etiology of insulin-dependent diabetes mellitus (IDDM). Annals of Medicine 1991;23:447–452.
  99. Gerstein HC: Cow’s milk exposure and type I diabetes mellitus—a important overview of the clinical literature. Diabetes Care 1994;17: 13–19.
  100. Norris JM, Scott FW: A meta-analysis of infant diet regimen and insulin-dependent diabetes mellitus: do biases play a role? Epidemiology 1996;7:87–92.
  101. Norris JM, Beaty B, Klingensmith G, et al.: Lack of association between early exposure to cow’s milk healthy protein and beta-cell autoimmunity. Diabetes Autoimmunity Study in the Young (DAISY). JAMA 1996;276(8):609–614.
  102. Virtanen SM, Hypponen E, Laara E, et al.: Cow’s milk consumption, disease-associated autoantibodies and type 1 diabetes mellitus: a follow-up study in siblings of diabetic children. Childhood Diabetes in Finland Study Group. Diabetic Medicine 1998;15(9): 730–738.
  103. Knip M, Virtanen SM, Becker D, et al.: Early feeding and risk of type 1 diabetes: experiences from the Trial to Reduce Insulin-dependent diabetes mellitus in the Genetically at Risk (TRIGR). American Diary of Clinical Nourishment 2011;94(6 Suppl): 1814S–1820S.
  104. Norris JM, Barriga K, Klingensmith G, et al.: Timing of first cereal exposure in infancy and risk of islet autoimmunity. JAMA 2003;290(13):1713–1720.
  105. Ziegler AG, Schmid S, Huber D, et al.: Early infant feeding and risk of creating type 1 diabetes-associated autoantibodies. JAMA 2003;290(13):1721–1728.
  106. Hummel S, Pfluger M, Hummel M, et al.: Primary dietary intervention study to reduce the risk of islet autoimmunity in youngsters at increased risk for type 1 diabetes: the BABYDIET study. Diabetes Care 2011;34(6):1301–1305.
  107. Mathieu C, Laureys J, Sobis H, et al.: 1,25-dihydroxyvitamin D3 prevents insulitis in NOD mice. Diabetes 1992;41:1491–1495.
  108. Hypponen E, Laara E, Reunanen A, et al.: Consumption of vitamin D and risk of type 1 diabetes: a birth-cohort study. Lancet 2001;358(9292):1500–1503.
  109. Stene LC, Ulriksen J, Magnus P, Joner G: Use of cod liver oil throughout pregnancy associated along with reduced risk of Type I diabetes in the offspring. Diabetologia 2000;43(9):1093–1098.
  110. Simpson M, Brady H, Yin X, et al.: No association of vitamin D Consumption or 25-hydroxyvitamin D levels in childhood along with risk of islet autoimmunity and type 1 diabetes: the Diabetes Autoimmunity Study in the Young (DAISY). Diabetologia 2011; 54(11):2779–2788.
  111. Fronczak CM, Baron AE, Hunt HP, et al.: In utero dietary exposures and risk of islet autoimmunity in children. Diabetes Care 2003;26(12):3237–3242.
  112. Marjamaki L, Niinisto S, Kenward MG, et al.: Maternal Consumption of vitamin D throughout pregnancy and risk of advanced beta cell autoimmunity and type 1 diabetes in offspring. Diabetologia 2010; 53(8):1599–1607.
  113. Norris JM, Yin X, Lamb MM, et al.: Omega-3 polyunsaturated fatty acid Consumption and islet autoimmunity in youngsters at increased risk for type 1 diabetes. JAMA 2007;298(12):1420–1428.
  114. Miller MR, Yin X, Seifert J, et al.: Erythrocyte membrane omega-3 fatty acid levels and omega-3 fatty acid Consumption are not associated along with conversion to type 1 diabetes in youngsters along with islet autoimmunity: the Diabetes Autoimmunity Study in the Young (DAISY). Pediatric Diabetes 2011;12(8):669–675.
  115. Skyler JS: Update on international efforts to stay away from type 1 diabetes. Annals of the N Y Academy of Sciences 2008;1150:190–196.
  116. Rewers M, Atkinson M: The feasible role of enteroviruses in diabetes mellitus. In: Rotbart HA (ed.) Human Enterovirus Infections. Washington, DC: ASM, 1996, pp. 353–385.
  117. Virtanen SM, Laara E, Hypponen E, et al.: Cow’s milk consumption, HLA-DQB1 genotype, and type 1 diabetes: a nested case-regulate study of siblings of youngsters along with diabetes. Childhood Diabetes in Finland Study Group [in process citation]. Diabetes 2000;49(6):912–917.
  118. Pinkey JH, Bingley PJ, Sawtell PA, et al.: Presentation and progress of childhood diabetes mellitus: a prospective population based study. The Bart’s-Oxford Study Group. Diabetologia 1994; 37(1):70–74.
  119. Foulis AK, Liddle CN, Farquharson MA, et al.: The histopathology of the pancreas in type I diabetes (insulin dependent) mellitus: a 25-year review of deaths in patients under twenty years of age in the United Kingdom. Diabetologia 1986;29(5):267–274.
  120. Childhood Diabetes Research Committee–Ministry of good health and Welfare–Japan; Polish Diabetes Research Group–Poznan; The Netherlands Institute for Preventive good health Care–Leiden; Diabetes Research focus of Pittsburgh–Pennsylvania: exactly how regularly do youngsters die at the onset of insulin-dependent diabetes? Analyses of registry data from Japan, Poland, the Netherlands, and Allegheny County, Pennsylvania. Diabetes, Nourishment & Metabolism 1990;3:57–62.
  121. Sabbah E, Savola K, Kulmala P, et al.: Diabetes-associated autoantibodies in relation to clinical characteristics and natural road in youngsters along with newly diagnosed type 1 diabetes.The Childhood Diabetes in Finland Study Group. Diary of Clinical Endocrinology & Metabolism 1999;84(5):1534–1539.
  122. Ortqvist E, Falorni A, Scheynius A, et al.: Age governs gender-dependent islet cell autoreactivity and predicts the clinical road in childhood IDDM. Acta Paediatrica 1997; 86(11):1166–1171.
  123. Pipeleers D, Ling Z: Pancreatic beta cells in insulin-dependent diabetes. Diabetes/Metabolism Reviews 1992;8(3):209–227.
  124. Rewers A, Hunt HP, Mackenzie T, et al.: Predictors of acute problems in youngsters along with type 1 diabetes. JAMA 2002;287(19):2511–2518.
  125. Secrest AM, Becker DJ, Kelsey SF, et al.: All-induce mortality trends in a large population-based cohort along with long-status childhood-onset type 1 diabetes: the Allegheny County type 1 diabetes registry. Diabetes Care 2010;33(12):2573–2579.
  126. Miller RG, Secrest AM, Sharma RK, et al.: Improvements in the life expectancy of type 1 diabetes: the Pittsburgh Epidemiology of Diabetes problems Study cohort. Diabetes 2012; 61(11):2987–2992.
  127. Orchard TJ, Secrest AM, Miller RG, Costacou T: In the absence of renal disease, twenty year mortality risk in type 1 diabetes is comparable to that of the general population: a report from the Pittsburgh Epidemiology of Diabetes problems Study. Diabetologia 2010;53(11):2312–2319.

Share this